Prostamax

It's like buying a "prostate tonic" where the impressive lab photos on the box are of one ingredient, but the jar contains a completely different one — and the only customer testimonials come from the manufacturer's own neighbourhood, written decades ago, with nobody else able to check them.

Two distinct proposed mechanisms map onto the two products. The synthetic KEDP tetrapeptide is claimed to act epigenetically: small DNA-binding peptides in the Khavinson family are reported to unwind tightly packed (hetero)chromatin in ageing cells and reactivate previously silenced genes, including ribosomal RNA genes, supposedly nudging prostate tissue toward a more youthful regulatory state. The bovine-prostate extract (Libidon/Prostatilen lineage) is instead a mixture of small peptides claimed to have tissue tropism for the prostate, exerting anti-inflammatory, antioxidant, antiplatelet/microcirculatory and immunomodulatory effects on prostate stroma and epithelium. Neither mechanism has a defined receptor or validated human target; the chromatin work is in cultured cells and the tissue-specificity claims rest largely on animal and Russian clinical observation.

Research contexts. Not proven uses, and not recommendations.

There is essentially no acceptable human evidence for the synthetic KEDP peptide that grey-market vendors sell as injectable "Prostamax" — its data are cell-culture (chromatin decondensation in aged lymphocytes) and rat prostatitis models. The human studies that marketing leans on belong to the related bovine-prostate extract lineage (Prostatilen, and Cytomax products like Libidon). Russian clinical literature spanning roughly three decades reports benefit in chronic prostatitis, BPH and associated fertility/sexual complaints — for example, anti-inflammatory and immunomodulating effects with improved urination in complicated prostatitis. But these reports are overwhelmingly small, single-centre, frequently uncontrolled or open-label, published mainly in Russian-language journals, and have not been independently replicated or confirmed in a high-quality international randomised controlled trial. For an oral supplement, the further problem is plausibility: intact peptides are largely digested, so oral "Cytomax" capsules delivering an active peptide to the prostate is biologically dubious and untested. Bottom line: thin, low-quality human data on a tissue extract, and none on the defined synthetic molecule.

• !The name covers two different substances (a synthetic tetrapeptide vs a cow-prostate extract); marketing applies cell/animal findings from one to the pills people actually buy.
• !Almost all human data come from one Russian research lineage, are small/uncontrolled, and have never been independently replicated to international standards.
• !Oral 'bioregulator' capsules are biologically implausible — peptides are mostly broken down in digestion before reaching the prostate.
• !Grey-market injectable 'Prostamax' is an unlicensed research chemical with no quality control, sterility guarantee, or proven contents.
• !Self-treating prostate symptoms (urinary trouble, pelvic pain) with an unproven peptide can delay diagnosis of treatable conditions, including prostate cancer.
• !Animal-tissue extracts carry theoretical contamination/immunogenicity concerns and inconsistent batch composition.

Neither the synthetic KEDP peptide nor the bovine-prostate Cytomax extract is a licensed medicine in the UK; the MHRA has authorised no such product. Prostatilen and the Khavinson Cytomaxes are Russian products with no UK marketing authorisation. Injectable "Prostamax" vials are sold as "research chemicals" / "not for human consumption", which places them outside the regulated medicines system — supplying an unlicensed product as a treatment for prostate disease would breach the Human Medicines Regulations 2012. Oral "Libidon" capsules imported as supplements have no recognised UK food-supplement or medicinal status and make health claims that would not be permitted under UK rules. In short: unlicensed, unregulated, and not something a UK clinician can prescribe or recommend.

• · N/A· None identified

  No registered international randomised controlled trial of synthetic Prostamax (KEDP)

  No completed or registered Western/international RCT for the synthetic peptide; evidence is preclinical only.

• · Not standardised· Reported (low quality)

  Russian-tradition clinical reports of the prostate peptide extract (Prostatilen lineage) in chronic prostatitis and BPH

  Mostly small, open-label, single-centre, Russian-language; not independently replicated.

1. 01
   Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects — Khavinson V.Kh., Lezhava T.A., Malinin V.V., Bulletin of Experimental Biology and Medicine (2004)

   In-vitro/cell study including Prostamax (KEDP); reports chromatin decondensation and rRNA gene activation in lymphocytes of subjects aged 75-88. Not a clinical efficacy trial.

2. 02
   Polypeptide prostatilen in the treatment of patients with complicated prostatitis — Boiko N.I., Likars'ka Sprava (Lik Sprava) (2004)

   Russian/Ukrainian-language clinical report on the related bovine-prostate extract Prostatilen, not the synthetic Prostamax peptide. Small, non-international-standard evidence.

3. 03
   Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and 30-year experience of clinical application in urology — Kuzmin I.V., Borovets S.Yu., Gorbachev A.G., Al-Shukri S.Kh., Urology Reports (St. Petersburg) / Urologicheskie vedomosti (2020)

   Review of the prostate peptide extract lineage (vol 10, no 3, pp 243-258); useful for the extract's claimed effects but is a narrative review from the originating tradition, not independent RCT evidence.

4. 04
   Possibilities of using bioregulatory peptide in prostate diseases (Prostatex) — review — Gadzhieva Z.K., Urologiia (2024)

   Recent Russian-language review of prostate bioregulatory peptide (Prostatex) use; review, not original human trial of Prostamax.

5. 05
   Prostamax / KEDP / Libidon — PubMed search — Various, PubMed (2026)

   Search confirms human literature attaches to the prostate extract (prostatilen), not the synthetic KEDP molecule; no high-quality international RCT of either.